

## First non-melanoma skin cancer patients treated with the Rhenium-SCT<sup>®</sup> in Austria

FOR IMMEDIATE RELEASE

28<sup>th</sup> October 2021

**Vienna, Austria, 28<sup>th</sup> October 2021:** OncoBeta<sup>®</sup> GmbH, a medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers (NMSCs), is pleased to announce the launch of its non-invasive skin cancer therapy Rhenium-SCT<sup>®</sup> (Skin Cancer Therapy) in Austria. Austria represents an important milestone in the development of OncoBeta's growing global distribution network.

The global incidence of non-melanoma skin cancers (NMSCs) continues to rise, with more than 7 million NMSC cases reported globally each year.<sup>1</sup> Austria has been ranked as 15<sup>th</sup> in the incidence of non-melanoma skin cancer in the world.<sup>2</sup>

The Rhenium-SCT<sup>®</sup> is a painless\*, non-invasive procedure, providing unparalleled aesthetic results, even in cases otherwise considered difficult to treat.<sup>3,4,7</sup> Rhenium-SCT<sup>®</sup> is an epidermal radioisotope therapy that is ideal for the targeted treatment of superficial skin cancers. It uses the localised and direct cell-killing effect of beta-radiation to trigger the death of cancer cells and local reactions of the immune system for the body to repair itself.<sup>3,5-7</sup>

On 21 October, Professor Siroos Mirzaei and his clinical team from Clinic Ottakring, have applied the first Rhenium-SCT<sup>®</sup> therapy in Vienna.

Head of the Department of Nuclear Medicine, Professor Mirzaei, says, "I've been working in the field of nuclear medicine for over 20 years. The non-invasive local treatment of non-melanoma skin cancer with Rhenium-188 is a great alternative treatment option we now have available for the first time in Austria. This treatment has been shown to improve patient outcomes and their quality of life. The treatment will be performed in tight cooperation with our Department of Dermatology."



OncoBeta<sup>®</sup> CEO Shannon D. Brown III says, "With thousands of patients already treated with Rhenium-SCT<sup>®</sup> around the world, we are excited to now be offering our ground-breaking treatment to patients in Austria, as part of our commitment to improving the quality of life and treatment options for skin cancer sufferers worldwide."

Rhenium-SCT<sup>®</sup> will be provided to patients in Austria by OncoBeta's distribution partner, DSD Pharma.

OncoBeta's Rhenium-SCT<sup>®</sup> is currently available in Australia, South Africa, Italy, Germany, Switzerland and now Austria as part of its planned global roll-out.

## About the Rhenium-SCT® (Skin Cancer Therapy)

Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans. The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.<sup>8</sup>

The Rhenium-SCT® is a painless\*, single session†, non-invasive therapy providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat.<sup>3,4,7</sup> The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT® is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT® compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® in one single session<sup>†7</sup>. Scar-free healing<sup>7</sup> of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment<sup>7</sup>.

## About OncoBeta®

OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta® has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta® has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at [www.oncobeta.com](http://www.oncobeta.com)

Follow us on social media:

LinkedIn: <https://www.linkedin.com/company/oncobeta-gmbh/>

Facebook: <https://www.facebook.com/oncobeta/>

Instagram: [https://www.instagram.com/oncobeta\\_gmbh/](https://www.instagram.com/oncobeta_gmbh/)

## About DSD Pharma

DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.

Find out more about DSD Pharma at [www.dsd-pharma.com](http://www.dsd-pharma.com)

## Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

\*No reported pain<sup>3,4</sup>

†Complete tumour regression in 98.5% of lesions treated, with 89% after a single application<sup>7</sup>

## References

1. Global Burden of Disease Cancer Collaboration, et al. *JAMA Oncol.* 2019;5(12):1749-1768.
2. World Cancer Research Fund. Skin Cancer Statistics. <https://www.wcrf.org/dietandcancer/skin-cancer-statistics/> (accessed October 2021).
3. Cipriani C, et al. *J Dermatolog Treat.* 2020:1-7.
4. Sedda AF, et al. *Clin Exp Dermatol.* 2008;33(6):745-749.
5. Lee CL, et al. *Transl Cancer Res.* 2013;2(5):412-421.
6. Arenas M, et al. *Strahlenther Onkol.* 2012;188(11):975-81.
7. Cipriani C, et al. Epidermal Radionuclide Therapy - Dermatological High-Dose-Rate. Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma. In: *Therapeutic Nuclear Medicine*, editor Baum RP; New York: Springer, 2014.
8. Cancer.net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. <https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention> (accessed October 2021).